Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma.

Hahn AW, Pal SK, Agarwal N.

Oncologist. 2019 Oct 15. pii: theoncologist.2019-0657. doi: 10.1634/theoncologist.2019-0657. [Epub ahead of print] No abstract available.

PMID:
31615950
2.

First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD.

Eur Urol Oncol. 2019 Nov;2(6):708-715. doi: 10.1016/j.euo.2019.09.002. Epub 2019 Oct 4. Review.

PMID:
31588018
3.

Elucidation of Structure-Activity Correlations in a Nickel Manganese Oxide Oxygen Evolution Reaction Catalyst by Operando Ni L-Edge X-ray Absorption Spectroscopy and 2p3d Resonant Inelastic X-ray Scattering.

Al Samarai M, Hahn AW, Beheshti Askari A, Cui YT, Yamazoe K, Miyawaki J, Harada Y, Rüdiger O, DeBeer S.

ACS Appl Mater Interfaces. 2019 Oct 23;11(42):38595-38605. doi: 10.1021/acsami.9b06752. Epub 2019 Oct 8.

PMID:
31523947
4.

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N.

Oncologist. 2019 Sep 6. pii: theoncologist.2019-0599. doi: 10.1634/theoncologist.2019-0599. [Epub ahead of print]

PMID:
31492769
5.

Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients.

Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N.

J Geriatr Oncol. 2019 Aug 8. pii: S1879-4068(19)30128-6. doi: 10.1016/j.jgo.2019.07.002. [Epub ahead of print] No abstract available.

PMID:
31402176
6.

From Ylides to Doubly Yldiide-Bridged Iron(II) High Spin Dimers via Self-Protolysis.

Yogendra S, Weyhermüller T, Hahn AW, DeBeer S.

Inorg Chem. 2019 Jul 15;58(14):9358-9367. doi: 10.1021/acs.inorgchem.9b01086. Epub 2019 Jul 1.

7.

Spectroscopic and Quantum Chemical Investigation of Benzene-1,2-dithiolate-Coordinated Diiron Complexes with Relevance to Dinitrogen Activation.

Kalläne SI, Hahn AW, Weyhermüller T, Bill E, Neese F, DeBeer S, van Gastel M.

Inorg Chem. 2019 Apr 15;58(8):5111-5125. doi: 10.1021/acs.inorgchem.9b00177. Epub 2019 Mar 25.

PMID:
30907584
8.

The Role of PD-L1 Testing in Advanced Genitourinary Malignancies.

Hahn AW, Sirohi D, Agarwal N.

Eur Urol Focus. 2019 Mar 11. pii: S2405-4569(19)30078-1. doi: 10.1016/j.euf.2019.03.003. [Epub ahead of print]

PMID:
30872123
9.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

10.

Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.

Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL.

Drugs Aging. 2019 May;36(5):395-401. doi: 10.1007/s40266-019-00644-1. Review.

PMID:
30784023
11.

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.

Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N.

Urol Oncol. 2019 Jun;37(6):352.e19-352.e24. doi: 10.1016/j.urolonc.2019.01.029. Epub 2019 Feb 13.

PMID:
30770300
12.

Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time.

Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N.

Cancer Treat Res Commun. 2019;19:100120. doi: 10.1016/j.ctarc.2019.100120. Epub 2019 Feb 6.

PMID:
30743187
13.

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.

Curr Treat Options Oncol. 2019 Feb 11;20(2):14. doi: 10.1007/s11864-019-0611-z. Review.

PMID:
30741354
14.

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.

Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N.

PLoS One. 2019 Jan 25;14(1):e0210415. doi: 10.1371/journal.pone.0210415. eCollection 2019.

15.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
16.

Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC).

Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N.

Mol Cancer Ther. 2019 Mar;18(3):726-729. doi: 10.1158/1535-7163.MCT-18-0739. Epub 2018 Dec 26.

PMID:
30587554
17.

Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment.

Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:363-371. doi: 10.1200/EDBK_200967. Review.

PMID:
30231388
18.

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).

Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW.

World J Oncol. 2018 Aug;9(4):119-122. doi: 10.14740/wjon1144w. Epub 2018 Sep 6.

19.

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome.

Hahn AW, Pal SK, Agarwal N.

Oncologist. 2019 Feb;24(2):143-145. doi: 10.1634/theoncologist.2018-0443. Epub 2018 Aug 23. No abstract available.

20.

Probing the Valence Electronic Structure of Low-Spin Ferrous and Ferric Complexes Using 2p3d Resonant Inelastic X-ray Scattering (RIXS).

Hahn AW, Van Kuiken BE, Chilkuri VG, Levin N, Bill E, Weyhermüller T, Nicolaou A, Miyawaki J, Harada Y, DeBeer S.

Inorg Chem. 2018 Aug 6;57(15):9515-9530. doi: 10.1021/acs.inorgchem.8b01550. Epub 2018 Jul 25.

PMID:
30044087
21.

Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis.

Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N.

J Geriatr Oncol. 2019 Jan;10(1):149-154. doi: 10.1016/j.jgo.2018.05.010. Epub 2018 Jun 1.

PMID:
29861146
22.

Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma.

Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD, Agarwal N.

Clin Genitourin Cancer. 2018 Oct;16(5):365-368. doi: 10.1016/j.clgc.2018.05.001. Epub 2018 May 29.

PMID:
29858123
23.

Electronic Spectra of Iron-Sulfur Complexes Measured by 2p3d RIXS Spectroscopy.

Van Kuiken BE, Hahn AW, Nayyar B, Schiewer CE, Lee SC, Meyer F, Weyhermüller T, Nicolaou A, Cui YT, Miyawaki J, Harada Y, DeBeer S.

Inorg Chem. 2018 Jun 18;57(12):7355-7361. doi: 10.1021/acs.inorgchem.8b01010. Epub 2018 May 30.

PMID:
29847108
24.

Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.

Hahn AW, Gill DM, Nussenzveig RH, Poole A, Farnham J, Cannon-Albright L, Agarwal N.

Clin Genitourin Cancer. 2018 Aug;16(4):288-292. doi: 10.1016/j.clgc.2018.03.006. Epub 2018 Mar 27.

PMID:
29674118
25.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.

Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P.

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

26.

Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma.

Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT.

Sci Rep. 2018 Mar 6;8(1):4044. doi: 10.1038/s41598-018-22425-3.

27.

The Role of Circulating Tumor DNA in Renal Cell Carcinoma.

Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK.

Curr Treat Options Oncol. 2018 Feb 20;19(2):10. doi: 10.1007/s11864-018-0530-4. Review.

PMID:
29464405
28.

Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.

Gill DM, Hahn AW, Hale P, Maughan BL.

Curr Treat Options Oncol. 2018 Jan 24;19(1):6. doi: 10.1007/s11864-018-0517-1. Review.

PMID:
29368125
29.

HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer.

Hahn AW, Pal SK, Agarwal N.

JAMA Oncol. 2018 Apr 1;4(4):562-563. doi: 10.1001/jamaoncol.2017.3158. No abstract available.

PMID:
29049481
30.

Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer.

Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N.

Clin Genitourin Cancer. 2017 Sep 6. pii: S1558-7673(17)30272-0. doi: 10.1016/j.clgc.2017.08.017. [Epub ahead of print]

PMID:
28958675
31.

Blood- and tissue-based tumor genomics: a battle royale or match made in heaven?

Hahn AW, Nussenzveig RH, Pal SK, Agarwal N.

Ann Oncol. 2017 Oct 1;28(10):2333-2335. doi: 10.1093/annonc/mdx418. No abstract available.

PMID:
28945831
32.

PD-1 checkpoint inhibition: Toxicities and management.

Hahn AW, Gill DM, Agarwal N, Maughan BL.

Urol Oncol. 2017 Dec;35(12):701-707. doi: 10.1016/j.urolonc.2017.08.005. Epub 2017 Sep 8.

PMID:
28889921
33.

Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer.

Hahn AW, Hale P, Rathi N, Agarwal N.

Curr Opin Urol. 2017 Nov;27(6):559-565. doi: 10.1097/MOU.0000000000000443. Review.

PMID:
28816716
34.

Current Treatment Landscape of Advanced Papillary Renal Cancer.

Shuch B, Hahn AW, Agarwal N.

J Clin Oncol. 2017 Sep 10;35(26):2981-2983. doi: 10.1200/JCO.2017.74.3328. Epub 2017 Jul 24. No abstract available.

PMID:
28737973
35.

Measurement of the Ligand Field Spectra of Ferrous and Ferric Iron Chlorides Using 2p3d RIXS.

Hahn AW, Van Kuiken BE, Al Samarai M, Atanasov M, Weyhermüller T, Cui YT, Miyawaki J, Harada Y, Nicolaou A, DeBeer S.

Inorg Chem. 2017 Jul 17;56(14):8203-8211. doi: 10.1021/acs.inorgchem.7b00940. Epub 2017 Jun 27.

PMID:
28653856
36.

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

Hahn AW, Gill DM, Pal SK, Agarwal N.

Immunotherapy. 2017 Jun;9(8):681-692. doi: 10.2217/imt-2017-0024. Review.

PMID:
28653573
37.

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications.

Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N.

Oncotarget. 2017 May 16;8(20):33614-33620. doi: 10.18632/oncotarget.16833.

38.

9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma.

Patel DA, Hahn AW, Martin MG.

Med Oncol. 2017 May;34(5):95. doi: 10.1007/s12032-017-0957-7. Epub 2017 Apr 13. No abstract available.

PMID:
28409436
39.

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer.

Agarwal N, Hahn AW, Gill DM, Farnham JM, Poole AI, Cannon-Albright L.

JAMA Oncol. 2017 Jun 1;3(6):856-857. doi: 10.1001/jamaoncol.2017.0147. No abstract available.

40.

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

Bowen RC, Hahn AW, Butler TW, Khong HT.

Mol Clin Oncol. 2017 Jan;6(1):122-124. doi: 10.3892/mco.2016.1090. Epub 2016 Nov 23.

41.

Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.

Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N.

BMC Urol. 2017 Jan 5;17(1):1. doi: 10.1186/s12894-016-0192-0.

42.

Measuring Spin-Allowed and Spin-Forbidden d-d Excitations in Vanadium Complexes with 2p3d Resonant Inelastic X-ray Scattering.

Van Kuiken BE, Hahn AW, Maganas D, DeBeer S.

Inorg Chem. 2016 Nov 7;55(21):11497-11501. Epub 2016 Oct 12.

PMID:
27731986
43.

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.

Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N.

Ecancermedicalscience. 2016 Sep 29;10:676. eCollection 2016.

44.

Immunotherapy of advanced renal cell carcinoma: Current and future therapies.

Gill D, Hahn AW, Sonpavde G, Agarwal N.

Hum Vaccin Immunother. 2016 Dec;12(12):2997-3004. doi: 10.1080/21645515.2016.1212794. Epub 2016 Aug 5. Review.

45.

Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract.

Hahn AW, Giri S, Pathak R, Bhatt VR, Martin MG.

Anticancer Res. 2016 Aug;36(8):4051-5.

PMID:
27466512
46.

New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.

Hahn AW, Jain R, Spach DH.

Med Clin North Am. 2016 Jul;100(4):911-26. doi: 10.1016/j.mcna.2016.03.012. Epub 2016 Apr 16. Review.

PMID:
27235621
47.

X-ray Absorption and Emission Spectroscopic Studies of [L2Fe2S2](n) Model Complexes: Implications for the Experimental Evaluation of Redox States in Iron-Sulfur Clusters.

Kowalska JK, Hahn AW, Albers A, Schiewer CE, Bjornsson R, Lima FA, Meyer F, DeBeer S.

Inorg Chem. 2016 May 2;55(9):4485-97. doi: 10.1021/acs.inorgchem.6b00295. Epub 2016 Apr 20.

48.

Precision medicine: lessons learned from the SHIVA trial.

Hahn AW, Martin MG.

Lancet Oncol. 2015 Dec;16(16):e580-1. doi: 10.1016/S1470-2045(15)00458-1. No abstract available.

PMID:
26678198
49.

Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis.

Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG.

J Natl Compr Canc Netw. 2015 Oct;13(10):1181-5.

PMID:
26483058
50.

How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia.

Hahn AW, Jamy O, Nunnery S, Yaghmour G, Giri S, Pathak R, Martin MG.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):646-54. doi: 10.1016/j.clml.2015.07.646. Epub 2015 Aug 5. Review.

PMID:
26386907

Supplemental Content

Support Center